CURE’s cervical cancer page is an extensive resource of cancer information featuring the latest cervical cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on cervical cancer.
September 14th 2024
Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.
Patients With Cervical Cancer Survivor Can Thrive With Social Support
January 31st 2024“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.
Tivdak Confers 30% Reduction in Mortality Risk in Cervical Cancer
October 22nd 2023A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.
Keytruda Plus Chemoradiotherapy Bests Standard of Care in Advanced Cervical Cancer
October 20th 2023Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Cervical Cancer Survivor Donates Embryos to Fellow Survivor to Help Fulfill Dream of Motherhood
August 25th 2022Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.
Cancer Vaccine-Tecentriq Combo Elicits ‘Very Encouraging’ Outcomes in Advanced Cervical Cancer
May 10th 2022Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.
Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer
March 25th 2022AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.
Novel Therapy May Address ‘High Unmet Clinical Need’ in Recurrent/Metastatic Cervical Cancer
April 28th 2021Treatment with tisotumab vedotin, a novel antibody-drug conjugate, in women with recurrent or metastatic cervical cancer, led to an objective response rate of 24% with a manageable safety profile.